TP53 and breast carcinoma: Therefore, our findings need to be followed up in larger cohorts of breast cancer patient samples, exploiting the long amplicon ddPCR assays to quantitate the individual TP53 transcripts in parallel to generating information about TP53 mutation status and copy number, to provide a truly integrative perspective of the biological roles and clinical implications of TP53 isoforms in breast cancer.